Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Pharma Is Quietly Expanding Ties to Indian Generic Manufacturers

This article was originally published in PharmAsia News

Executive Summary

U.S. pharmaceutical companies have been trekking to India for a while to carry out clinical trials. But the relationships with Indian drug manufacturers have been quietly growing and now encompass the entire industry, according to a leader in the Indian pharmaceutical industry

You may also be interested in...



Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs

NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster

Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs

NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster

PharmAsia News Spotlight On India: Smaller R&D Units To Dominate India - Study

MUMBAI - India, which has now found a respectable place for itself on the global drug R&D map, could increasingly see smaller dedicated R&D units power the escalating research momentum in the country

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel